Sage Therapeutics(SAGE) - 2023 Q4 - Earnings Call Presentation

2 Chris Benecchi Chief Business Officer Laura Gault Chief Medical Officer Sage Therapeutics © 2024 3 ZURZUVAE First and only oral product approved by the FDA specifically for postpartum depression (second approved product) Sage Therapeutics © 2024 The COVID-19 Pandemic had a significant effect on perinatal mental health outcomes13-15 4 Strong financial foundation to help create value for sustained growth Important Safety Information ZURZUVAE may cause serious side effects, including decreased awareness and ...